Meeder Asset Management’s Seres Therapeutics MCRB Stock Holding History

Meeder Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-70	Closed	-$9K	–	1840
2021 Q3	$9K	Buy	+70	New	+$13.7K	﹤0.01%	1706
2021 Q2	–	Sell	-64	Closed	-$26K	–	2596
2021 Q1	$26K	Buy	+64	New	+$29.5K	﹤0.01%	1334
2020 Q4	–	Sell	-132	Closed	-$74K	–	2065
2020 Q3	$74K	Buy	132 +91	+222%	+$30.3K	﹤0.01%	865
2020 Q2	$3K	Buy	41 +4	+11%	+$351	﹤0.01%	1677
2020 Q1	$3K	Buy	+37	New	+$2.48K	﹤0.01%	1967
2019 Q2	–	Sell	-35	Closed	-$5K	–	2095
2019 Q1	$5K	Buy	+35	New	+$4.27K	﹤0.01%	1393
2017 Q4	–	Sell	-2	Closed	-$1K	–	1734
2017 Q3	$1K	Sell	2 -43	-96%	-$11.8K	﹤0.01%	1552
2017 Q2	$10K	Sell	45 -14	-24%	-$2.88K	﹤0.01%	992
2017 Q1	$13K	Sell	59 -40	-40%	-$8.12K	﹤0.01%	795
2016 Q4	$20K	Buy	+99	New	+$21.6K	﹤0.01%	654

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Meeder Asset Management's MCRB Position: Q4 2021 in Review

Meeder Asset Management sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 70 shares — an estimated $9K sold.

Meeder Asset Management first reported a position in MCRB in Q4 2016 and held it in 10 quarters. The position peaked at $74K in Q3 2020. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

Meeder Asset Management reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 70 Seres Therapeutics shares in Q4 2021, an estimated $9K.
Meeder Asset Management first reported a position in Seres Therapeutics in Q4 2016 and held it in 10 quarters.
Meeder Asset Management's Seres Therapeutics position peaked at $74K in Q3 2020.
148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.